Xencor, Inc.
XNCR Real Time Price USDRecent trades of XNCR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by XNCR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
XNCR Revenue by Segment or Geography
New patents grants
-
Patent Title: Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof Mar. 04, 2025
-
Patent Title: Il-12 heterodimeric fc-fusion proteins Feb. 25, 2025
-
Patent Title: Fc variants with altered binding to fcrn Feb. 04, 2025
-
Patent Title: Heterodimeric antibodies that bind fibroblast activation protein Dec. 31, 2024
-
Patent Title: Bispecific and monospecific antibodies using novel anti-pd-1 sequences Nov. 26, 2024
-
Patent Title: Targeted heterodimeric fc fusion proteins containing il-15 il-15alpha and antigen binding domains Nov. 12, 2024
-
Patent Title: Heterodimeric antibodies that bind cd3 and cd38 Oct. 29, 2024
-
Patent Title: Heterodimeric antibodies that bind somatostatin receptor 2 Aug. 06, 2024
-
Patent Title: Untargeted and targeted il-10 fc-fusion proteins Jun. 11, 2024
-
Patent Title: Dosing of a bispecific antibody that binds cd20 and cd3 May. 21, 2024
-
Patent Title: Engineered il-2 fc fusion proteins May. 14, 2024
-
Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Apr. 02, 2024
-
Patent Title: Fc variants with altered binding to fcrn Mar. 19, 2024
-
Patent Title: Anti-cd28 compositions Mar. 05, 2024
-
Patent Title: Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 Mar. 05, 2024
-
Patent Title: Heterodimeric antibodies that bind cd3 and gpc3 Jan. 02, 2024
-
Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Jan. 02, 2024
-
Patent Title: Targeted il-12 heterodimeric fc-fusion proteins Dec. 26, 2023
-
Patent Title: Bispecific antibodies that bind to cd38 and cd3 Dec. 12, 2023
-
Patent Title: Optimized fc variants Nov. 21, 2023
-
Patent Title: Heterodimeric proteins Nov. 14, 2023
-
Patent Title: Heterodimeric antibodies that bind cd3 and cldn6 Aug. 29, 2023
-
Patent Title: Optimized antibody variable regions Aug. 08, 2023
-
Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Jun. 13, 2023
-
Patent Title: Il-12 heterodimeric fc-fusion proteins May. 23, 2023
-
Patent Title: Heterodimeric proteins Apr. 25, 2023
-
Patent Title: Heterodimeric antibodies that bind cd3 and psma Apr. 11, 2023
-
Patent Title: Optimized antibodies that target cd19 Apr. 04, 2023
-
Patent Title: Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains Apr. 04, 2023
-
Patent Title: Anti-cd28 compositions Feb. 28, 2023
-
Patent Title: Bispecific heterodimeric fusion proteins containing il-15-il-15ralpha fc-fusion proteins and immune checkpoint antibody fragments Feb. 21, 2023
-
Patent Title: Compositions and methods for treating ige-mediated disorders Jan. 31, 2023
-
Patent Title: Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof Dec. 13, 2022
-
Patent Title: Il-7-fc-fusion proteins Nov. 29, 2022
-
Patent Title: Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains Nov. 22, 2022
-
Patent Title: Bispecific checkpoint inhibitor antibodies Nov. 08, 2022
-
Patent Title: Heterodimeric antibodies that bind enpp3 and cd3 Oct. 18, 2022
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Sep. 20, 2022
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells Sep. 06, 2022
-
Patent Title: Heterodimeric fc variants Aug. 02, 2022
-
Patent Title: Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof Jul. 05, 2022
-
Patent Title: Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases Jun. 21, 2022
-
Patent Title: Methods of treating neurological diseases Jun. 21, 2022
-
Patent Title: Il-12 heterodimeric fc-fusion proteins Jun. 14, 2022
-
Patent Title: Heterodimeric antibodies that bind cd3 and cd38 Jun. 07, 2022
-
Patent Title: Ctla4-ig immunoadhesins Jun. 07, 2022
-
Patent Title: Engineered il-2 fc fusion proteins May. 03, 2022
-
Patent Title: Bispecific and monospecific antibodies using novel anti-pd-1 sequences Apr. 26, 2022
-
Patent Title: Heterodimeric proteins Apr. 12, 2022
-
Patent Title: Ctla4-ig immunoadhesins Feb. 22, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to XNCR
Recent picks made for XNCR stock on CNBC
ETFs with the largest estimated holdings in XNCR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $XNCR stock a Buy, Sell, or Hold?
- What is the price target for $XNCR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $XNCR stock?
- Who owns the most shares of $XNCR stock?
- What funds own $XNCR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XNCR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.